These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8429674)

  • 81. Structural modifications of bryostatin 2.
    Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
    Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
    [TBL] [Abstract][Full Text] [Related]  

  • 82. An improved source of bryostatin 10, Bugula neritina from the Gulf of Aomori, Japan.
    Kamano Y; Zhang HP; Hino A; Yoshida M; Pettit GR; Herald CL; Itokawa H
    J Nat Prod; 1995 Dec; 58(12):1868-75. PubMed ID: 8691208
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices.
    Schaufelberger DE; Koleck MP; Beutler JA; Vatakis AM; Alvarado AB; Andrews P; Marzo LV; Muschik GM; Roach J; Ross JT
    J Nat Prod; 1991; 54(5):1265-70. PubMed ID: 1800630
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Unintended target effect of anti-BCL-2 DNAi.
    Ebrahim AS; Kandouz M; Emara N; Sugalski AB; Lipovich L; Al-Katib AM
    Cancer Manag Res; 2017; 9():427-432. PubMed ID: 28989285
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.
    Barr PM; Lazarus HM; Cooper BW; Schluchter MD; Panneerselvam A; Jacobberger JW; Hsu JW; Janakiraman N; Simic A; Dowlati A; Remick SC
    Am J Hematol; 2009 Aug; 84(8):484-7. PubMed ID: 19536846
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
    Blackhall FH; Ranson M; Radford JA; Hancock BW; Soukop M; McGown AT; Robbins A; Halbert G; Jayson GC;
    Br J Cancer; 2001 Feb; 84(4):465-9. PubMed ID: 11263437
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The clinical development of the bryostatins.
    Clamp A; Jayson GC
    Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
    Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A
    Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors.
    Li Y; Mohammad RM; al-Katib A; Varterasian ML; Chen B
    Leuk Res; 1997 May; 21(5):391-7. PubMed ID: 9225065
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
    Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
    Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Bryostatin 1 induces ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia cells.
    Mohammad RM; Maki A; Pettit GR; al-Katib AM
    Enzyme Protein; 1996; 49(5-6):262-72. PubMed ID: 9252784
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.
    Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
    Leuk Res; 1993 Jan; 17(1):1-8. PubMed ID: 8429674
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
    Steube KG; Drexler HG
    Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.